Samsung Biologics
300, Songdo bio-daero
Yeonsu-gu
Incheon
21987
South Korea
Tel: 032-455-3336
Email: recruit.bio2@samsung.com
20 articles about Samsung Biologics
-
Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)
3/18/2024
Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
-
Samsung Biologics awarded Leadership status by CDP for climate action efforts
2/13/2024
Samsung Biologics, a global contract development and manufacturing organization, announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project.
-
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing
2/7/2024
Samsung Biologics today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.
-
Samsung Introduces Lunit AI Solutions for Enhanced Chest Screenings
1/25/2024
Boston Imaging announced that Samsung has signed a supply contract with Lunit Inc., a leading provider of artificial intelligence powered solutions for cancer diagnostics and therapeutics, to enable faster and more accurate chest screenings for timely interventions with improved patient outcomes.
-
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2023 Financial Results
1/24/2024
Samsung Biologics announced robust financial results for the fourth quarter and fiscal year 2023.
-
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
1/22/2024
Samsung Biologics, a global contract development and manufacturing organization, announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.
-
Samsung Biologics presents 2024 business plans at J.P. Morgan Healthcare Conference
1/10/2024
Samsung Biologics presented its 2024 business plans and strategy at the J.P. Morgan Healthcare Conference held in San Francisco, California.
-
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
1/8/2024
Flagship Pioneering, the bioplatform innovation company, and Samsung announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine.
-
Samsung Biologics reports third quarter 2023 financial results
10/25/2023
Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the third quarter of fiscal year 2023.
-
Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma's portfolio companies
10/23/2023
Samsung Biologics and Kurma Partners announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners' portfolio companies.
-
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
9/18/2023
Samsung Biologics announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.
-
The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.
-
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs
8/24/2023
Samsung Biologics, a global contract development and manufacturing organization, announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.
-
Samsung Biologics Reports Second Quarter 2023 Financial Results
7/26/2023
Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the second quarter of fiscal year 2023.
-
Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility
7/18/2023
Samsung Biologics, a global contract development and manufacturing organization, released its 2023 Environmental, Social and Governance Report.
-
The pharmaceutical giant is tapping the world’s largest biomanufacturing facility operated by Samsung Biologics for biosimilar production.
-
Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025
6/6/2023
While attending the 2023 BIO International Convention, Samsung Biologics, a leading contract development and manufacturing organization, revealed details of the company's future expansion plan to have its new fifth plant operational by April 2025.
-
Samsung Biologics Reports First Quarter 2023 Financial Results
4/24/2023
Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2023.
-
Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion
3/17/2023
Samsung Biologics, a leading contract development and manufacturing organization, announced that the company will commence the construction of a fifth plant as part of its strategic expansion in response to increased market demand.
-
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
1/27/2023
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year 2022.